Schilder R J, Shea T C
Peripheral Stem Cell Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Semin Oncol. 1998 Jun;25(3):349-55.
Recent advances in hematopoietic support have extended the application of high-dose chemotherapy in the treatment of malignancy. The use of colony-stimulating factors and peripheral blood progenitor cells significantly have decreased the morbidity and mortality of such treatment compared with traditional autologous bone marrow transplantation. These innovations facilitate the use of multiple cycles of high-dose chemotherapy as consolidation after achieving best response to conventional chemotherapy or as initial treatment. Developing data suggest that this approach in both of these settings merit further evaluation for the treatment of epithelial ovarian carcinoma.
造血支持方面的最新进展扩大了大剂量化疗在恶性肿瘤治疗中的应用。与传统的自体骨髓移植相比，集落刺激因子和外周血祖细胞的使用显著降低了此类治疗的发病率和死亡率。这些创新有助于在对传统化疗取得最佳反应后使用多个周期的大剂量化疗进行巩固治疗，或作为初始治疗。不断发展的数据表明，这种方法在这两种情况下对于上皮性卵巢癌的治疗都值得进一步评估。
